On Jan. 04, Sun Anthony Y divested U.S. $1,394,907 in shares of Zentalis Pharmaceuticals Inc.. The Pres, CEO sold 26,794 shares at a price per share of $52.06. The transaction decreased this specific insider’s holdings to 2,965,113 shares worth around $144.43 million at present.
Another 10,000 shares were sold by Gallagher Cam, for more than $519,323 in total proceeds. The Dir dumped the shares at a price of $51.93 and the insider now owns almost 570,192 shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
That same day, Bunker Kevin D. sold 34,987 shares. The COO divested U.S. $1,821,116 in shares of Zentalis Pharmaceuticals Inc. at a price per share of $52.05. The transaction decreased this specific insider’s holdings to 1,101,493 shares worth around $53653724.03 at present.
Epperly Melissa B, sold 3,083 shares. The CFO divested U.S. $160,034 in shares of Zentalis Pharmaceuticals Inc. at a price per share of $51.91. The transaction decreased this specific insider’s holdings to 274,596 shares worth around $13375571.16 at present.
Cantor Fitzgerald launched its Zentalis Pharmaceuticals Inc. [ZNTL] rating to the equivalent of an Overweight and assigned the price target of $44, in a research note dated September 29, 2020. That figure represents around a -10.7% premium from where the company’s shares closed on Wednesday. Some new analysts also started their coverage, with Cantor Fitzgerald’s analysts assigning the shares to “an Overweight” rating in a research note to investors issued in late September. Meanwhile, H.C. Wainwright had launched its coverage on ZNTL with “Buy”, in a research note produced for clients August 27, 2020. In addition, there was a new coverage from SVB Leerink on April 28, 2020. The research firm rated ZNTL “an Outperform”.
ZNTL Price Performance
On Wall Street, Zentalis Pharmaceuticals Inc. [NASDAQ:ZNTL] finished Wednesday’s session down -6.54% at $48.71. The stock went up to $52.28 at the same session while its lowest single day price was $46.83. In the last five days, it saw a fall of about -10.69%, Zentalis Pharmaceuticals Inc. shares dropped by almost -6.22% since the beginning of the year. However, the share price has dropped to as low as -20.53% below its one year high.
ZNTL Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 46.27 level, and in case of violation of this particular level, it will cause more drop to 43.82 level. On the upper level, 54.72 is still the key resistance. The stock may increase to the subsequent resistance at 51.72. The Relative Strength Index (RSI) pinned on the 14-day chart is 42.99, implying a neutral technical stance while the MACD stands at -2.04, meaning price will decrease in the next trading period. Percent R indicator moved to 84.11%, implying bearish price movement. Stochastic %K at 26.75% suggest holding the stock.
What is the short interest in Zentalis Pharmaceuticals Inc.?
Short interest in the Zentalis Pharmaceuticals Inc. stock has surged, increasing by 0.24 million shares to total 1.9 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 2.14 million, data from Yahoo Finance shows. The decrease of -12.63% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 11.75% of the overall float for the stock.
Zentalis Pharmaceuticals Inc.’s Biggest Shareholders: Who Owns Zentalis Pharmaceuticals Inc. [ZNTL]?
Filings by Viking Global Investors LP showed that the firm now holds a total of 3,943,284 shares or roughly 9.71% of the outstanding ZNTL shares. This means their shares have reduced by -500,000 from the 3,943,284 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Matrix Capital Management Co. LP updated stake is worth $194,755,819. Details in the latest 13F filings reveal that Fidelity Management & Research Co acquired their 23.36% stake valued at $145,272,691 while Tybourne Capital Management cut theirs at $135,778,283. During the last quarter, Fidelity Management & Research Co raised 539,774 of its shares in Zentalis Pharmaceuticals Inc.. The Redmile Group LLC’s holdings currently number 2,432,408 shares at $118482593.68. According to the firm’s last 13F report, Citadel Advisors LLC shares in the company at filing stood at 1,689,634 shares, roughly $86,103,749.
What are analyst thoughts on Zentalis Pharmaceuticals Inc.?
Looking forward to the Zentalis Pharmaceuticals Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Zentalis Pharmaceuticals Inc. stock at $60.00 within the next 12 months, which represents almost 18.82 per cent growth from its previous closing price of $48.71. The highest analysts’ target for Zentalis Pharmaceuticals Inc. stock projections is $75.00 and the lowest one is $43.00. Still, 5 analysts sharing their consensus rating for ZNTL stock in 2021 agree that it is a Buy.